Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC